sis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The companys flagship product, KYNAMRO injection, is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia for the reduction of low-density lipoprotein cholesterol. It also has a pipeline of 28 drugs in development for the treatment of cardiovascular, severe and rare, neurologic, and metabolic diseases, as well as cancer. The company has collaboration agreements with AstraZeneca to discover and develop antisense drugs against five cancer targets; Biogen Idec to develop and commercialize ISIS-SMNRx for the treatment of spinal muscular atrophy; and Bristol-Myers Squibb to discover, develop, and commercialize antisense drugs targeting proprotein convertase subtilisin/kexin type 9. In addition, it has strategic alliances with Eli Lilly and Company for the development of LY2275796, an antisense inhibitor of eIF-4E; Genzyme Corporation for the licensing and co-development of KYNAMRO; and GlaxoSmithKline to develop drugs against targets for rare and serious diseases, including infectious diseases and conditions causing blindness. Isis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
There is nothing scary but very unique way of finding medicine for diseases which are impossible to be druged by any other method. If they find cure for say some cancers this stock will cross few hundred in a zippy.